quarta-feira, 30 de junho de 2010
domingo, 27 de junho de 2010
sexta-feira, 25 de junho de 2010
Humani corporis fabrica
Melhor que estudar em figuras é observar as peças preparadas pelo técnica inovadora de dissecção humana pelo grupo de Pequim.
Os corpos passam por um tratamento que leva cerca de um ano e meio e envolve acetona e silicone líquido, que é enrijecido para simular o tônus natural. Depois disso, cada músculo é pintado cuidadosamente com os tons que ostentavam quando seus donos ainda estavam vivos.
Para download do livro de Vesalius...
http://www.divshare.com/download/11812808-34f
Fisiologia aplicada em terapia intensiva: livro
download: http://www.divshare.com/download/11811695-38d
Transfusion Medicine: Livro
Transfusion medicine: a clinical guide
Livro de boa leitura e rápida sobre o assunto.
Download: http://www.divshare.com/download/11811696-560
Sugammadex
Sugammadex: Another Milestone in Clinical Neuromuscular Pharmacology
Sugammadex is a revolutionary investigational reversal drug currently undergoing Phase III testing whose introduction into clinical practice may change the face of clinical neuromuscular pharmacology. A modified -cyclodextrin, sugammadex exerts its effect by forming very tight water-soluble complexes at a 1:1 ratio with steroidal neuromuscular blocking drugs (rocuronium vecuronium pancuronium). During rocuronium-induced neuromuscular blockade, the IV administration of sugammadex creates a concentration gradient favoring the movement of rocuronium molecules from the neuromuscular junction back into the plasma, which results in
a fast recovery of neuromuscular function. Sugammadex is biologically inactive, does not bind to plasma proteins, and appears to be safe and well tolerated.
Additionally, it has no effect on acetylcholinesterase or any receptor system in the body. The compound’s efficacy as an antagonist does not appear to rely on renal excretion of the cyclodextrin-relaxant complex. Human and animal studies have demonstrated that sugammadex can reverse very deep neuromuscular blockade induced by rocuronium without muscle weakness. Its future clinical use should decrease the incidence of postoperative muscle weakness, and thus contribute to increased patient safety.
Sugammadex will also facilitate the use of rocuronium for rapid sequence induction of anesthesia by providing a faster onset-offset profile than that seen with 1.0 mg/kg succinylcholine. Furthermore, no additional anticholinesterase or anticholinergic drugs would be needed for antagonism of residual neuromuscular blockade, which would mean the end of the cardiovascular and other side effects of these compounds. The clinical use of sugammadex promises to eliminate many of the shortcomings in our current practice
with regard to the antagonism of rocuronium and possibly other steroidal neuromuscular blockers.
Anesthesia e analgesia
Vol. 104, No. 3, March 2007
Download: http://www.divshare.com/download/11811693-50d
Sugammadex is a revolutionary investigational reversal drug currently undergoing Phase III testing whose introduction into clinical practice may change the face of clinical neuromuscular pharmacology. A modified -cyclodextrin, sugammadex exerts its effect by forming very tight water-soluble complexes at a 1:1 ratio with steroidal neuromuscular blocking drugs (rocuronium vecuronium pancuronium). During rocuronium-induced neuromuscular blockade, the IV administration of sugammadex creates a concentration gradient favoring the movement of rocuronium molecules from the neuromuscular junction back into the plasma, which results in
a fast recovery of neuromuscular function. Sugammadex is biologically inactive, does not bind to plasma proteins, and appears to be safe and well tolerated.
Additionally, it has no effect on acetylcholinesterase or any receptor system in the body. The compound’s efficacy as an antagonist does not appear to rely on renal excretion of the cyclodextrin-relaxant complex. Human and animal studies have demonstrated that sugammadex can reverse very deep neuromuscular blockade induced by rocuronium without muscle weakness. Its future clinical use should decrease the incidence of postoperative muscle weakness, and thus contribute to increased patient safety.
Sugammadex will also facilitate the use of rocuronium for rapid sequence induction of anesthesia by providing a faster onset-offset profile than that seen with 1.0 mg/kg succinylcholine. Furthermore, no additional anticholinesterase or anticholinergic drugs would be needed for antagonism of residual neuromuscular blockade, which would mean the end of the cardiovascular and other side effects of these compounds. The clinical use of sugammadex promises to eliminate many of the shortcomings in our current practice
with regard to the antagonism of rocuronium and possibly other steroidal neuromuscular blockers.
Anesthesia e analgesia
Vol. 104, No. 3, March 2007
Download: http://www.divshare.com/download/11811693-50d
Goodbye Suxamethonium!
No drugs in anaesthesia are more problematic than suxamethonium. Yet, no drugs have survived as
suxamethonium does in spite of crisis after crisis, and attempt after attempt at its replacement. For
decades, suxamethonium has taught us neuromuscular pharmacology and provided us with an
encyclopaedia of side effects, while benefiting millions and millions of our anaesthetised patients.
With the arrival of sugammadex, it finally appears that suxamethonium can be retired. Suxamethonium
has done its job and seen its days! The present review is intended to offer a eulogy for
suxamethonium.
C. Lee
Anaesthesia, 2009, 64 (Suppl. 1), pages 73–81
download http://www.divshare.com/download/11811692-c8a
suxamethonium does in spite of crisis after crisis, and attempt after attempt at its replacement. For
decades, suxamethonium has taught us neuromuscular pharmacology and provided us with an
encyclopaedia of side effects, while benefiting millions and millions of our anaesthetised patients.
With the arrival of sugammadex, it finally appears that suxamethonium can be retired. Suxamethonium
has done its job and seen its days! The present review is intended to offer a eulogy for
suxamethonium.
C. Lee
Anaesthesia, 2009, 64 (Suppl. 1), pages 73–81
download http://www.divshare.com/download/11811692-c8a
Achei o anestesiador on Twitpic
Grande dupla! @anestesiador e @gustavoolivetti;
Bo,s tempos no corredor do INCOR há 13 anos....
@anestesiador e Sra(anestesiadora) no burburinho do COPA on Twitpic
@anestesiador e Sra(anestesiadora) no burburinho do COPA on Twitpic
Na festa do Congresso Pauslita de Anestesiologia
2010!
2010!
sábado, 12 de junho de 2010
Comer, Beber, Viver
GRAFFIGNA
Vista: Rojo violáceo intenso
Nariz: Frutas rojas clavo, canela, ahumado, vainilla
Boca: Sabroso, equilibrado, con toque de madera nueva que se ensambla con los taninos
Guarda: Listo para beber, pero se recomienda una guarda de 8 años... ótimo...vamos beber com 5 anos
Uva: 100% Malbec
Cosecha: 2005
Región de Cultivo: Valle del Pedernal, San Juan, Argentina A 1.400 m sobre nivel del mar
Maceración con Hollejo: 21 Días
Fermentación Alcohólica: 7 días
Añejamiento en Roble: 50% en roble francés y 50% en roble americano durante 12 meses
Maduración en Botella 6 meses
Vista: Rojo violáceo intenso
Nariz: Frutas rojas clavo, canela, ahumado, vainilla
Boca: Sabroso, equilibrado, con toque de madera nueva que se ensambla con los taninos
Guarda: Listo para beber, pero se recomienda una guarda de 8 años... ótimo...vamos beber com 5 anos
Uva: 100% Malbec
Cosecha: 2005
Región de Cultivo: Valle del Pedernal, San Juan, Argentina A 1.400 m sobre nivel del mar
Maceración con Hollejo: 21 Días
Fermentación Alcohólica: 7 días
Añejamiento en Roble: 50% en roble francés y 50% en roble americano durante 12 meses
Maduración en Botella 6 meses
Risco de Broncoaspiração na obesidade
Check out this SlideShare Presentation:
Risco de Broncoaspiração na obesidade
View more presentations from Pablo Braga Gusman.
terça-feira, 8 de junho de 2010
Copa do Mundo 2006
Bom ver que a vida continua.... foto da copa de 2006!
Jogo Brasil e França!
Eram 4 torcendo para o Brasil e apenas um torcedor francês....
Nem pude comemorar a vitória francesa devido a decepção das demais torcedoras....
Mas esse ano vai dar França na cabeça!
terça-feira, 1 de junho de 2010
Esportes radicais
O Francês Taïg Khris bateu no sábado 29 de maio o recorde mundial de salto em patins. Instalado em uma plataforma na altura do Primeiro andar da Torre Eiffel, desceu pela maoir plataforma já construída (30 metros) após uma queda livre de 10 metros!
Na realidade, muitos patinadores usam o Trocadero para suas acrobacias. Vimos dois meio malucos pulando por um fio a uma altura de mais de 2 metros.
Dia Mundial sem Tabaco
Dia Mundial Sem Tabaco
Parar de fumar é capaz de impedir a progressão da DPOC (doença pulmonar obstrutiva crônica), além de reduzir os riscos de desenvolver câncer de pulmão, infarto do miocárdio, acidente vascular cerebral (derrame) e outras doenças. Mesmo para aquelas pessoas que têm o hábito de fumar, há muitos anos, sempre haverá benefícios ao parar de fumar. Esses ganhos se darão em termos de uma vida mais saudável, com menos propensão a adoecer.
Conheça alguns:
- 12 horas após: O nível de monóxido de carbono no sangue cai, ficando próximo ao normal.
- 1 mês após: Começa a melhorar a capacidade respiratória, com diminuição da falta de ar e da tosse.
- 1 ano após: O risco de ter um ataque cardíaco estará em torno da metade do que tinha quando fumava.
- 5 anos após: O risco de ter derrame diminui e fica próximo ao de uma pessoa que nunca fumou.
- 10 anos após: O risco de ter câncer de pulmão estará reduzido à metade.
- 15 anos após: O risco de sofrer doenças cardíacas igualará ao de uma pessoa que nunca fumou.
Assinar:
Postagens (Atom)